Stratec Se

Stratec Se EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of Stratec Se (SBS.DE) as of Oct 16, 2026 is 27.38. In the previous year, EV/EBIT (Enterprise Value to EBIT) was 8.35 — a change of 227.93% (higher).

EV/EBIT

27.38

YoY

227.93%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Stratec Se is 2025 27.38 . EV/EBIT (Enterprise Value to EBIT) of Stratec Se was 2024 8.35 . It decreases by 227.93% higher compared to the previous year.

The Stratec Se EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBIT
Date
EV/EBIT
Jan 1, 2019
12.93 EUR
Jan 1, 2020
7.02 EUR
Jan 1, 2021
4.74 EUR
Jan 1, 2022
5.60 EUR
Jan 1, 2023
8.37 EUR
Jan 1, 2024
8.35 EUR
Jan 1, 2025
27.38 EUR
Jan 1, 2026 (e)
8.74 EUR
The Stratec Se EV/EBIT history
YEAREV/EBITYoY
est8.74-68.08%
27.38+227.93%
8.35-0.21%
8.37+49.33%
5.60+18.18%
4.74-32.48%
7.02-45.68%
12.93-15.51%
15.30+98.36%
7.71-20.68%
9.72+11.04%
8.76-10.50%
9.78-47.84%
18.76-35.78%
29.21+66.25%
17.57-19.77%
21.90-1.97%
22.34-34.12%
33.91+347.36%
7.58+16.08%
6.53—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Stratec Se Valuation

Details

Historical Valuation Multiples

ⓘ

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Stratec Se's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Stratec Se's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Stratec Se's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Stratec Se grows earnings faster than its peers.

Stratec Se Stock analysis

What does Stratec Se do? The company Stratec SE is a German company operating in the medical technology industry. It was founded in 1984 and has since become a leading provider of automation solutions and diagnostic instruments. Stratec's business model is based on the development and production of devices and systems used in medical diagnostics. The company focuses in particular on the areas of immunology, clinical chemistry, and hematology. Stratec also offers innovative solutions in microscopy and cell analysis. In the "automation solutions" division, Stratec develops systems for the automation of laboratory processes. These are mainly used in clinical diagnostics to accelerate and simplify workflow. Examples include sample identification systems, pipetting robots, and analysis devices. In the "in vitro diagnostics" division, Stratec offers products for determining blood values. This includes devices for determining glucose, cholesterol, and hemoglobin levels, as well as devices for infection diagnostics and tumor and allergy diagnostics. Another division of Stratec is "microscopy." The company manufactures automated microscope systems, primarily used in biomedical research to analyze cells and tissues. In the "cell analysis" division, Stratec offers innovative methods for analyzing cells, such as cell growth and vitality determination. Stratec always focuses on tailoring the design of its products to the needs of its customers. High flexibility in device development and manufacturing is therefore an important factor in the company's success. In addition to device development and production, Stratec also provides services related to its products. These include installation, maintenance, and on-site repair of devices for customers. Stratec SE operates internationally and has branches in Europe, Asia, and America. The company employs over 1,000 people worldwide. Overall, Stratec SE is a successful and renowned provider of medical devices and systems for automating laboratory processes. With its diverse product portfolio and high flexibility in customer support, Stratec has earned a leading position in the industry. Stratec Se is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Stratec Se stock

EV/EBIT (Enterprise Value to EBIT) of Stratec Se is 27.38 in 2025.

EV/EBIT (Enterprise Value to EBIT) of Stratec Se changed from 8.35 to 27.38, representing a 227.93% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) Stratec Se since 2006 – with annual values, charts, and detailed analysis.

The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.

EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes

To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s Stratec Se with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Stratec Se

All Key Metrics — Stratec Se